NASDAQ:CPRX

Catalyst Pharmaceuticals (CPRX) Stock Forecast, Price & News

$11.63

-0.06 (-0.51%)

(As of 01:45 PM ET)

Compare

Today's Range: $11.55
▼
$11.86
50-Day Range: $11.69
▼
$15.02
52-Week Range: $11.09
▼
$22.11

Volume: 413,937 shs
Average Volume: 1.85 million shs
Market Capitalization: $1.24 billion

P/E Ratio: 11.51
Dividend Yield: N/A
Price Target: $24.75

Catalyst Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 110.3% Upside
$24.75 Price Target
Short Interest: Bearish
8.67% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.99
Upright™ Environmental Score
News Sentiment: 1.00
Based on 7 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 68.97%
From $0.87 to $1.47 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.75 out of 5 stars

Medical Sector

85th out of 969 stocks

Pharmaceutical Preparations Industry

25th out of 453 stocks

3.5

Analyst's Opinion

Consensus Rating
Catalyst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $24.75, Catalyst Pharmaceuticals has a forecasted upside of 110.3% from its current price of $11.77.
Amount of Analyst Coverage
Catalyst Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
8.67% of the float of Catalyst Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Catalyst Pharmaceuticals has a short interest ratio ("days to cover") of 6.2.
Change versus previous month
Short interest in Catalyst Pharmaceuticals has recently increased by 10.89%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Catalyst Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Catalyst Pharmaceuticals does not have a long track record of dividend growth.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Catalyst Pharmaceuticals has received a 52.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Amifampridine" and "Clinical research services for physiological diseases " products. See details.
Environmental Sustainability
The Environmental Impact score for Catalyst Pharmaceuticals is -1.99.

3.3

News and Social Media Coverage

News Sentiment
Catalyst Pharmaceuticals has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Catalyst Pharmaceuticals this week, compared to 5 articles on an average week.
Search Interest
Only 4 people have searched for CPRX on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.
MarketBeat Follows
13 people have added Catalyst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 30% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Catalyst Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
12.10% of the stock of Catalyst Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
77.27% of the stock of Catalyst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Catalyst Pharmaceuticals are expected to grow by 68.97% in the coming year, from $0.87 to $1.47 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Catalyst Pharmaceuticals is 11.65, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 108.38.
Price to Earnings Ratio vs. Sector
The P/E ratio of Catalyst Pharmaceuticals is 11.65, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 91.36.
Price to Book Value per Share Ratio
Catalyst Pharmaceuticals has a P/B Ratio of 4.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

CPRX Price History

30 days | 90 days | 365 days | Advanced Chart

CPRX Stock News Headlines

September 27, 2023 | finance.yahoo.com

If EPS Growth Is Important To You, Catalyst Pharmaceuticals (NASDAQ:CPRX) Presents An Opportunity

September 25, 2023 | americanbankingnews.com

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) to Post FY2024 Earnings of $1.33 Per Share, Zacks Research Forecasts

October 2, 2023 | Oxford Club (Ad)

Better Than Oil Stocks

The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.

September 21, 2023 | marketwatch.com

Catalyst Pharmaceuticals Inc. stock falls Thursday, still outperforms market

September 18, 2023 | finance.yahoo.com

Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference

September 9, 2023 | seekingalpha.com

Catalyst Pharmaceuticals launches $500M mixed shelf offering - filing

September 8, 2023 | finance.yahoo.com

Why Is Catalyst (CPRX) Down 14% Since Last Earnings Report?

September 8, 2023 | stocknews.com

September Buy, Sell or Hold for This Pharma Sock: Catalyst Pharmaceuticals (CPRX)

October 2, 2023 | Oxford Club (Ad)

Better Than Oil Stocks

The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.

September 6, 2023 | finance.yahoo.com

Unraveling the Future of Catalyst Pharmaceuticals Inc (CPRX): A Deep Dive into Key Metrics

August 30, 2023 | seekingalpha.com

Catalyst Pharmaceuticals: The Journey From Earnings Euphoria To Patent Perils

August 29, 2023 | stocknews.com

3 Pharma Stocks to Watch for Value in September

August 24, 2023 | stocknews.com

3 Value Pharma Stocks to Keep Watching

August 23, 2023 | msn.com

Cantor Fitzgerald Reiterates Catalyst Pharmaceuticals (CPRX) Overweight Recommendation

August 21, 2023 | stocknews.com

Catalyst Pharmaceuticals (CPRX): Is Now the Time to Buy This Pharma Stock?

August 16, 2023 | finance.yahoo.com

Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer

August 14, 2023 | finance.yahoo.com

Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress

August 12, 2023 | msn.com

Cantor Fitzgerald Maintains Catalyst Pharmaceuticals (CPRX) Overweight Recommendation

August 11, 2023 | markets.businessinsider.com

5 Analysts Have This to Say About Catalyst Pharmaceuticals

August 11, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Catalyst Pharma (CPRX)

August 11, 2023 | finance.yahoo.com

Catalyst Pharmaceuticals Second Quarter 2023 Earnings: EPS: US$0.35 (vs US$0.21 in 2Q 2022)

August 10, 2023 | finanznachrichten.de

Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update

August 9, 2023 | finance.yahoo.com

Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update

August 3, 2023 | stocknews.com

Which is the Better Value Stock for August: Catalyst Pharmaceuticals, Inc. (CPRX) vs. Teva Pharmaceutical Industries (TEVA)?

July 27, 2023 | bizjournals.com

Pharmaceutical CEO to retire from public company he co-founded

July 25, 2023 | finanznachrichten.de

Catalyst Pharmaceuticals, Inc.: Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-End

July 25, 2023 | marketwatch.com

Catalyst Pharmaceuticals: Patrick McEnany to Retire as CEO by Year-End >CPRX

See More Headlines

Receive CPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPRX Company Calendar

Last Earnings: 8/09/2023
Today: 10/02/2023
Next Earnings (Estimated): 11/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CPRX
CUSIP: N/A
CIK: 1369568
Web: www.catalystpharma.com
Phone: (305) 420-3200
Fax: 305-529-0933
Employees: 82
Year Founded: 2002

Price Target and Rating

Average Stock Price Forecast: $24.75
High Stock Price Forecast: $27.00
Low Stock Price Forecast: $24.00
Forecasted Upside/Downside: +111.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.01
Trailing P/E Ratio: 11.57
Forward P/E Ratio: 13.44
P/E Growth: N/A
Net Income: $83.08 million
Net Margins: 38.14%
Pretax Margin: 47.81%
Return on Equity: 36.13%
Return on Assets: 29.63%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.59
Quick Ratio: 4.38

Sales & Book Value

Annual Sales: $214.20 million
Price / Sales: 5.82
Cash Flow: $0.81 per share
Price / Cash Flow: 14.43
Book Value: $2.89 per share
Price / Book: 4.04

Miscellaneous

Outstanding Shares: 106,590,000
Free Float: 93,695,000
Market Cap: $1.25 billion
Optionable: Optionable
Beta: 1.11

Social Links

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Patrick J. McEnany (Age 76)
Co-Founder, Chairman, Pres & CEO
Comp: $1.2M

Ms. Alicia Grande C.M.A. (Age 52)
CPA, CMA, CPA, Chief Accounting Officer, VP, Treasurer & CFO
Comp: $667.91k

Dr. Steven R. Miller Ph.D. (Age 61)
COO & Chief Scientific Officer
Comp: $809.03k

Dr. Gary Ingenito M.D. (Age 67)
Ph.D., Chief Medical & Regulatory Officer
Comp: $751.85k

Mr. Jeffrey Del Carmen (Age 52)
Chief Commercial Officer
Comp: $711.7k

Ms. Mary Coleman
VP & Head of Investor Relations

Mr. Brian Elsbernd J.D. (Age 59)
Chief Compliance Officer & Chief Legal Officer

Mr. Pete Curry Sr.
VP of Sales

Dr. Stanley Iyadurai M.D.
Ph.D., Sr. VP of Medical Affairs & Drug Discovery

Dr. Preethi Sundaram Ph.D. (Age 47)
Chief Strategy Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CPRX Stock - Frequently Asked Questions

Should I buy or sell Catalyst Pharmaceuticals stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CPRX shares.
View CPRX analyst ratings or view top-rated stocks.
What is Catalyst Pharmaceuticals' stock price forecast for 2023?: 4 Wall Street analysts have issued twelve-month price targets for Catalyst Pharmaceuticals' stock. Their CPRX share price forecasts range from $24.00 to $27.00. On average, they expect the company's share price to reach $24.75 in the next twelve months. This suggests a possible upside of 111.7% from the stock's current price.
View analysts price targets for CPRX or view top-rated stocks among Wall Street analysts.
How have CPRX shares performed in 2023?: Catalyst Pharmaceuticals' stock was trading at $18.60 at the beginning of the year. Since then, CPRX shares have decreased by 37.2% and is now trading at $11.69.
View the best growth stocks for 2023 here.
Are investors shorting Catalyst Pharmaceuticals?: Catalyst Pharmaceuticals saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 7,940,000 shares, an increase of 10.9% from the August 31st total of 7,160,000 shares. Based on an average trading volume of 1,290,000 shares, the short-interest ratio is presently 6.2 days. Approximately 8.7% of the company's shares are sold short.
View Catalyst Pharmaceuticals' Short Interest.
When is Catalyst Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our CPRX earnings forecast.
How were Catalyst Pharmaceuticals' earnings last quarter?: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) issued its quarterly earnings data on Wednesday, August, 9th. The biopharmaceutical company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.08. The biopharmaceutical company earned $99.58 million during the quarter, compared to the consensus estimate of $92.77 million. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 36.13% and a net margin of 38.14%.

What ETFs hold Catalyst Pharmaceuticals' stock?: ETFs with the largest weight of Catalyst Pharmaceuticals (NASDAQ:CPRX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Invesco Biotechnology & Genome ETF (PBE), Janus Henderson Small Cap Growth Alpha ETF (JSML), SPDR S&P Biotech ETF (XBI), Invesco S&P SmallCap Health Care ETF (PSCH), ERShares NextGen Entrepreneurs ETF (ERSX), Invesco S&P SmallCap 600 Pure Growth ETF (RZG) and ALPS Medical Breakthroughs ETF (SBIO).
What guidance has Catalyst Pharmaceuticals issued on next quarter's earnings?: Catalyst Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, August, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $380.00 million-$390.00 million, compared to the consensus revenue estimate of $380.21 million.
What other stocks do shareholders of Catalyst Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD).
What is Catalyst Pharmaceuticals' stock symbol?: Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."
How do I buy shares of Catalyst Pharmaceuticals?: Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Catalyst Pharmaceuticals' stock price today?: One share of CPRX stock can currently be purchased for approximately $11.69.
How much money does Catalyst Pharmaceuticals make?: Catalyst Pharmaceuticals (NASDAQ:CPRX) has a market capitalization of $1.25 billion and generates $214.20 million in revenue each year. The biopharmaceutical company earns $83.08 million in net income (profit) each year or $1.01 on an earnings per share basis.
How can I contact Catalyst Pharmaceuticals?: Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The official website for the company is www.catalystpharma.com. The biopharmaceutical company can be reached via phone at (305) 420-3200, via email at bkorb@troutgroup.com, or via fax at 305-529-0933.

This page (NASDAQ:CPRX) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial